Alliance A031701: A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

Objective

This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

https://clinicaltrials.gov/ct2/show/NCT03609216

Location: Essentia Health Cancer Centers

Research Study Categories

• Adult Studies

Specialty

• Genitourinary Cancer

Contact

Cancer Clinical Trials at 218-786-3308
or cancertrials@essentiahealth.org